Imunon, Inc. (IMNN)Healthcare | Biotechnology | Lawrenceville, United States | NasdaqCM
1.60 USD
After hours: 1.60 |
Hot Take ↕ | Aug. 22, 2026, 6:08 a.m. EDT
The immediate outlook is severely clouded by a confluence of deteriorating fundamentals and aggressive short-term selling pressure. While the company recently secured $10 million in financing, the balance sheet remains precarious with debt significantly exceeding cash reserves, and the business is burning through free cash flow at a rapid pace. This financial strain is reflected in the stock's performance, which has suffered a catastrophic 99.8% decline over the last nine years, with the most recent annual period showing a steep 60% drop. The technical picture confirms this bearish sentiment, as the stock trades well below its 50-day and 200-day moving averages, indicating a persistent downtrend. Furthermore, the statistical forecasting model predicts a further 12% decline over the next 45 days, suggesting that even short-term bounces may be fleeting given the lack of a clear catalyst to reverse the trend. With no dividend history to provide income and a forward P/E that is negative due to losses, there is no margin of safety here; the market appears to be pricing in continued distress rather than a turnaround. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.058416 |
| AutoTheta | 0.063171 |
| MSTL | 0.146839 |
| AutoETS | 0.152320 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 1.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.248 |
| Excess Kurtosis | -0.95 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 187.293 |
| Market Cap | 8,978,245 |
| Forward P/E | -0.90 |
| Beta | 1.97 |
| Previous Name | Celsion Corporation |
| Website | https://imunon.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.72649574 |
| Address1 | 997 Lenox Drive |
| Address2 | Suite 100 |
| All Time High | 1,897,032.9 |
| All Time Low | 1.47 |
| Ask | 2.07 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 67,620 |
| Average Daily Volume3 Month | 126,756 |
| Average Volume | 126,756 |
| Average Volume10Days | 67,620 |
| Beta | 1.974 |
| Bid | 1.16 |
| Bid Size | 2 |
| Book Value | 0.415 |
| City | Lawrenceville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.6 |
| Current Ratio | 1.819 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.6469 |
| Day Low | 1.55 |
| Debt To Equity | 187.293 |
| Display Name | Imunon |
| Earnings Call Timestamp End | 1,747,062,000 |
| Earnings Call Timestamp Start | 1,747,062,000 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -14,545,411 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.84 |
| Enterprise Value | 12,211,080 |
| Eps Current Year | -2.335 |
| Eps Forward | -1.7725 |
| Eps Trailing Twelve Months | -2.89 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7206 |
| Fifty Day Average Change | -0.120599985 |
| Fifty Day Average Change Percent | -0.07009182 |
| Fifty Two Week Change Percent | -72.649574 |
| Fifty Two Week High | 6.04 |
| Fifty Two Week High Change | -4.44 |
| Fifty Two Week High Change Percent | -0.7350994 |
| Fifty Two Week Low | 1.47 |
| Fifty Two Week Low Change | 0.13 |
| Fifty Two Week Low Change Percent | 0.08843537 |
| Fifty Two Week Range | 1.47 - 6.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 920,298,600,000 |
| Float Shares | 5,311,305 |
| Forward Eps | -1.7725 |
| Forward P E | -0.9026798 |
| Free Cashflow | -9,529,312 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 1.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -409,917 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0514 |
| Held Percent Institutions | 0.05682 |
| Implied Shares Outstanding | 5,611,403 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,754,524,800 |
| Last Split Factor | 115:100 |
| Long Business Summary | Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey. |
| Long Name | Imunon, Inc. |
| Market | us_market |
| Market Cap | 8,978,245 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_260398 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -14,733,162 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,978,244 |
| Number Of Analyst Opinions | 5 |
| Open | 1.6 |
| Operating Cashflow | -15,108,816 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 5.03 |
| Phone | 609 896 9100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.6 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Celsion Corporation |
| Previous Close | 1.6 |
| Price Eps Current Year | -0.68522483 |
| Price Hint | 4 |
| Price To Book | 3.8554218 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.436 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.6469 |
| Regular Market Day Low | 1.55 |
| Regular Market Day Range | 1.55 - 1.6469 |
| Regular Market Open | 1.6 |
| Regular Market Previous Close | 1.6 |
| Regular Market Price | 1.6 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 82,345 |
| Return On Assets | -0.77992 |
| Return On Equity | -4.29724 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,611,403 |
| Shares Percent Shares Out | 0.0201 |
| Shares Short | 112,958 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 18,395 |
| Short Name | Imunon, Inc. |
| Short Percent Of Float | 0.0202 |
| Short Ratio | 0.5 |
| Source Interval | 15 |
| State | NJ |
| Symbol | IMNN |
| Target High Price | 25.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 13.0 |
| Total Cash | 6,864,378 |
| Total Cash Per Share | 1.223 |
| Total Debt | 7,845,292 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.8122 |
| Two Hundred Day Average Change | -1.2122 |
| Two Hundred Day Average Change Percent | -0.43105042 |
| Type Disp | Equity |
| Volume | 82,345 |
| Website | https://imunon.com |
| Zip | 8,648 |